---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-014813"
form_type: "8-K"
ticker: "ELTP"
cik: "0001053369"
company_name: "ELITE PHARMACEUTICALS INC /NV/"
filed_at: "2026-04-02T23:59:59+00:00"
generated_at: "2026-05-15T07:46:41.022919+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Elite Pharmaceuticals launches generic methadone tablets; addresses $22M market

## Summary
- Launched generic methadone HCl 5 mg and 10 mg tablets under Elite Laboratories label.
- Product indicated for severe persistent pain and opioid addiction detoxification/maintenance treatment.
- Annual retail sales for brand and generic methadone tablets approx. $22M (IQVIA 2025 data).
- Company operates a cGMP and DEA-registered R&D and manufacturing facility in Northvale, NJ.

## SEC filing metadata
- accession: 0001493152-26-014813
- form_type: 8-K
- ticker: ELTP
- cik: 0001053369
- company_name: ELITE PHARMACEUTICALS INC /NV/
- filed_at: 2026-04-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053369/000149315226014813/0001493152-26-014813-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053369/000149315226014813/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-014813
- JSON: https://secwatch.observer/filing/0001493152-26-014813.json
- Plain text: https://secwatch.observer/filing/0001493152-26-014813.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.